| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Q3 2026 total revenue of $23.1 million, including $22.9 million in RNS revenue representing 1% growth |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Q2 2026 total revenue of $22.8 million, including $22.5 million in RNS revenue representing 21% growth |
| 28 Jul 2026 |
8-K: Regulation FD Disclosure
— Company received communication from FDA indicating that the PMA Supplement for idiopathic generalized epilepsy is not approvable in its current form and that additional clinical evidence from the NAUTILUS trial and literature supportin... |
| 08 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 5, 2026, NeuroPace, Inc. held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) virtually via live webcast. The following proposals were voted upon, and the final voting results with respect to each such proposal are... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
Raises full year 2026 guidance to $99 million to $101 million, up from $98 million to $100 million previously |
| 03 Mar 2026 |
8-K: Results of Operations and Financial Condition
Reported quarterly revenue of $26.6 million in Q4 2025 representing 24% growth |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition
Reported record quarterly revenue of $27.4 million in Q3 2025 representing 30% growth |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition
Reported record quarterly revenue of $23.5 million in Q2 2025 |
| 24 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Williams Brings a Track Record of Leading Medical Device Public Companies as CFO |
| 12 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 6, 2025, NeuroPace, Inc. held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) virtually via live webcast. The following proposals were voted upon, and the final voting results with respect to each such proposal are... |
| 04 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more
Mountain View, Calif. – June 4, 2025 – NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company has entered into a new $75 million credit ... |
| 27 May 2025 |
8-K: Regulation FD Disclosure; Other Events
— NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy |
| 13 May 2025 |
8-K: Results of Operations and Financial Condition
Reported record quarterly revenue of $22.5 million in Q1 2025, driven by increasing market demand for core RNS System products |
| 14 Apr 2025 |
8-K: Regulation FD Disclosure
— Minimal expected impact to operations and financial results — |
| 02 Apr 2025 |
8-K: Regulation FD Disclosure; Other Events
— Beginning of Wind Down of Stereo EEG (SEEG) Distribution Relationship in Q4 2025 — |
| 04 Mar 2025 |
8-K: Results of Operations and Financial Condition
Completed an underwritten public offering of $74.8 million, using $49.5 million of the net proceeds to repurchase 100% of KCK holdings and $20.2 million to strengthen its balance sheet to support planned operations to reach cash flow bre... |
| 20 Feb 2025 |
8-K: Regulation FD Disclosure; Other Events
NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd. |
| 18 Feb 2025 |
8-K: Other Events
NeuroPace, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggreg... |
| 14 Feb 2025 |
8-K: Entry into a Material Definitive Agreement
On February 13, 2025, NeuroPace, Inc. (the “Company” or “NeuroPace”) and KCK Ltd. (“KCK”) entered into a stock purchase agreement (the “Repurchase Agreement”) pursuant to which the Company has agreed to repurchase all of the shares of it... |
| 28 Jan 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
— Three-year targets of 20% revenue CAGR and achievement of cash flow breakeven – |
Loading...